advertisement
Cambridge Antibody Technology is developing lerdelimumab (CAT 152), the lead in a series of human anti TGF β2 antibodies, for its potential in preventing postoperative scarring in patients undergoing surgery for glaucoma (trabulectomy). It also has potential for the treatment of fibrosis, cataract, retinopathy and connective tissue disease.
Dr. M.F. Cordeiro, Department of Pathology, Institute of Ophthalmology, Moorfields Eye Hospital, Bath Street, London EC1V 9EL, UK. m.cordeiro@ucl.ac.uk
12.8.10 Woundhealing antifibrosis (Part of: 12 Surgical treatment > 12.8 Filtering surgery)